Michele H. Mokrzycki MD

Dr. Mokrzycki received her B.S. from Boston College, M.D. from the University of Vermont College of Medicine, and a Masters of Science in Clinical Research from the Albert Einstein College of Medicine. She completed an Internal Medicine Residency and Fellowship at the University of Connecticut Health Science Center in Farmington, CT.

Dr Mokrzycki served on the Program Committee Member for the National Kidney Foundation (NKF) for 2 years, and on Faculty for the Therapeutic Apheresis Academy (TAA) for 5 years, which is held annually at the University of Virginia College of Medicine. She has been an invited speaker and/or chaired sessions at the American Society of Nephrology, NKF, TAA, the American Society of Diagnostic and Interventional Nephrology (ASDIN) and VEITH symposium. Dr. Mokrzycki is one of the founding members of the North American Vascular Access Society, which is a consortium of nephrologists in the United States and Canada with a common research interest in improving outcomes associated with hemodialysis vascular access.

Dr Mokrzycki's research interests have focused primarily on hemodialysis vascular access related complications, specifically, complications associated with tunneled catheter use such as infection/bacteremia/inflammation and dysfunction/thrombosis. Her publications include a randomized controlled trial of low dose warfarin to prevent hemodialysis catheter thrombosis, and a study of catheter bacteremia in HIV hemodialysis patients. She is the recipient of a grant from the AETNA Foundation to study the effect of a multidisciplinary team approach to improve outcomes associated with catheter bacteremia in hemodialysis patients. Dr Mokrzycki participated in a large NIH trial that reported on MYH9 as a major-effect risk gene for focal and segmental glomerulosclerosis (FSGS)

Other areas of research include complications associated with therapeutic apheresis procedures, and the use of plasmapheresis to remove digoxin-Antibody complexes in ESRD, outcomes associated with heparin-free dialysis, reverse transcriptase inhibitor associated lactic acidosis, protein losses associated with continuous renal replacement therapies (CVVH), the epidemiology of HIV associated nephropathy in the Bronx.